Aurobindo Pharma Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

June 25, 2026
Posted by: Neeraj Pandey
Category: News

Aurobindo Pharma Q1 Results FY27: Uniresearch projects Revenue Rs 9,064 Cr | PAT Rs 1,064 Cr (28-analyst consensus). Q4 FY26: Rev Rs 8,853 Cr | PAT Rs 921 Cr.

The Aurobindo Pharma Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 28-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 9,064 Cr (+15.2% YoY) and PAT Rs 1,064 Cr (+29.1% YoY). Prepared by Kunal Singla.

Click Here – Get Free Investment Predictions

Table of Contents

Aurobindo Pharma Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change	Source
Aurobindo Pharma Revenue (Rs Cr)	7,868	9,064	+15.2%	Uniresearch \| 28-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	824	1,064	+29.1%	Uniresearch \| 28-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 1,517	12-month view	–	Analyst consensus (28 analysts)

Predictions apply 28-analyst FY27 consensus (Rev +15.2%, PAT +29.1%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Aurobindo Pharma Q4 FY26 Key Metrics

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	8,853	+5.6% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	921	+2.0% YoY	Consolidated quarterly financial data

What Analysts Are Saying About Aurobindo Pharma

Across 28 analysts covering Aurobindo Pharma, the FY27 consensus projects revenue growth of +15.2% and profit growth of +29.1%, with an average 12-month price target of Rs 1,517.

Key Watchpoints for Aurobindo Pharma

Revenue Delivery vs Consensus

Whether Aurobindo Pharma delivers Revenue Rs 9,064 Cr (+15.2% consensus growth) is the primary watchpoint. Q1 FY26 base was Rs 7,868 Cr.

PAT Delivery in Q1 FY27

PAT is projected at Rs 1,064 Cr (+29.1% vs Q1 FY26 base of Rs 824 Cr). Q4 FY26 PAT was Rs 921 Cr.

Risks to the Aurobindo Pharma Prediction

Revenue Miss vs Consensus

Revenue falling below the +15.2% consensus would result in actual revenue below Rs 9,064 Cr.

PAT Pressure

Unexpected margin or cost factors could affect PAT delivery against the +29.1% growth consensus.

Conclusion: Aurobindo Pharma

The Aurobindo Pharma Uniresearch prediction of Revenue Rs 9,064 Cr and PAT Rs 1,064 Cr is derived from the 28-analyst FY27 consensus applied to verified Q1 FY26 actuals. Track live updates on Univest.

Track Aurobindo Pharma Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live Q1 FY27 alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals. These are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on Aurobindo Pharma

What is Uniresearch’s PAT prediction for Aurobindo Pharma Q1 Results FY27?

Ans. Uniresearch projects Aurobindo Pharma Q1 FY27 PAT at Rs 1,064 Cr (+29.1% consensus), based on Q1 FY26 actual PAT of Rs 824 Cr.

What is the Revenue prediction for Aurobindo Pharma Q1 Results FY27?

Ans. Aurobindo Pharma Q1 Revenue is projected at Rs 9,064 Cr, applying +15.2% FY27 revenue consensus to Q1 FY26 base of Rs 7,868 Cr.

What were Aurobindo Pharma Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 8,853 Cr (+5.6% YoY) and PAT was Rs 921 Cr (+2.0% YoY).

How many analysts back the Aurobindo Pharma Q1 Results FY27?

Ans. The Aurobindo Pharma Q1 prediction uses the 28-analyst FY27 consensus with an average 12-month target of Rs 1,517.

What FY27 growth consensus was applied for Aurobindo Pharma Q1 Results FY27?

Ans. Revenue growth of +15.2% and profit growth of +29.1% (28-analyst consensus).

What are the key risks to Aurobindo Pharma Q1 Results FY27?

Ans. Risks include revenue missing the +15.2% consensus target and PAT pressure beyond the +29.1% consensus.

What is the Q1 FY26 base for Aurobindo Pharma Q1 Results FY27?

Ans. Q1 FY26 consolidated Revenue Rs 7,868 Cr and PAT Rs 824 Cr.

News Q1 results

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.